Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept vs tacrolimus in pediatric steroid-resistant nephrotic syndrome (SRNS)
ChiCTR2500109037Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Sep 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of telitacicept in nephrosis (2 arms), sponsored by Children's Hospital of Chongqing Medical University. Primary endpoints: Safety and Urinary protein remission rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
nephrosis
Beyond the preview
Go deeper on ChiCTR2500109037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109037.